Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Wall Street Zen

Myriad Genetics (NASDAQ:MYGN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts have also commented on the company. Leerink Partners boosted their price target on Myriad Genetics from $5.00 to $8.00 and gave the stock a “market perform” rating in a research report on Thursday. Weiss Ratings cut Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 27th. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 15th. Stephens cut their target price on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 18th. Finally, Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a report on Tuesday, October 20th. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.55.

Myriad Genetics Stock Performance

Shares of MYGN stock opened at $5.92 on Friday. The firm has a market cap of $566.25 million, a price-to-earnings ratio of -4.35 and a beta of 1.62. The company’s 50 day moving average is $4.50 and its 200 day moving average is $4.62. The company has a quick ratio of 1.77, a current ratio of 1.98 and a debt-to-equity ratio of 0.45. Myriad Genetics has a 52-week low of $2.74 and a 52-week high of $8.09.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $202.70 million during the quarter, compared to analyst estimates of $191.33 million. Myriad Genetics had a negative return on equity of 19.87% and a negative net margin of 16.07%. On average, sell-side analysts anticipate that Myriad Genetics will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Myriad Genetics

A number of large investors have recently made changes to their positions in the business. Vise Technologies Inc. acquired a new stake in Myriad Genetics in the third quarter worth about $117,000. State of Wyoming increased its holdings in shares of Myriad Genetics by 9.5% during the third quarter. State of Wyoming now owns 117,979 shares of the company’s stock valued at $508,000 after acquiring an additional 10,196 shares in the last quarter. Pinnacle Associates Ltd. acquired a new position in shares of Myriad Genetics during the third quarter valued at about $44,000. Williams & Novak Wealth Management LLC purchased a new position in shares of Myriad Genetics in the 3rd quarter valued at approximately $67,000. Finally, Engineers Gate Manager LP boosted its stake in Myriad Genetics by 8.7% in the 2nd quarter. Engineers Gate Manager LP now owns 124,769 shares of the company’s stock worth $712,000 after purchasing an additional 9,970 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Key Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.